MetaVia (MTVA) Projected to Post Quarterly Earnings on Wednesday

MetaVia (NASDAQ:MTVA) is expected to be announcing its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.76) per share for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 11, 2026 at 12:30 PM ET.

MetaVia Stock Performance

Shares of MTVA stock opened at $1.42 on Wednesday. MetaVia has a fifty-two week low of $1.17 and a fifty-two week high of $19.03. The company has a 50 day moving average price of $1.45 and a 200 day moving average price of $5.06. The stock has a market capitalization of $7.33 million, a P/E ratio of -0.17 and a beta of 0.59.

Wall Street Analyst Weigh In

Several brokerages have commented on MTVA. HC Wainwright decreased their price target on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, March 27th. Wall Street Zen upgraded MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a report on Friday, April 24th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $26.50.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent SEC filing. Hedge funds and other institutional investors own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.